Avita Medical (RCEL) Price & Analysis

Compare

399 Followers

RCEL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.60 - $14.16

Previous CloseN/A

Volume824.49K

Average Volume (3M)351.26K

Market Cap

$154.39M

Enterprise Value$168.38M

Total Cash (Recent Filing)$15.69M

Total Debt (Recent Filing)$44.59M

Price to Earnings (P/E)―

Beta1.91

Next Earnings

Nov 06, 2025

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding26,618,935

10 Day Avg. Volume541,312

30 Day Avg. Volume351,258

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.09

Enterprise Value/Revenue2.25

Enterprise Value/Gross Profit2.67

Enterprise Value/Ebitda-3.77

Forecast

1Y Price Target

$8.70

Price Target Upside50.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Market PotentialAvita's expanded portfolio of wound care solutions drastically increases its total addressable market potential to over $3.5B.

Product LaunchThe company's recent commercial launch of new products suggests a revenue inflection may be on the near-term horizon.

Strategic AgreementsThe revised distribution agreement for PermeaDerm suggests that demand is surging and that the company is realizing sales synergies through a bolstered product portfolio.

Bears Say

Cash PositionRCEL's limited cash on hand, current operating cash burn, need for additional capital, and limits on how many shares can be issued exacerbate the downside risk.

Financial GuidanceAvita is now guiding to full-year revenue of $76M to $81M, reflecting growth of 19% to 27%, compared to the company's prior guidance of $100M to $106M.

Reimbursement IssuesReimbursement to providers via Medicare Administrative Contractors were not being paid despite submitting claims for usage.

Avita Medical News

Avita Medical completes Australian equity raise

AVITA Medical (RCEL) announced the completion of a private placement to institutional and professional investors in Australia to...

3d ago

RCEL

Avita Medical assumed with a Buy at Lake Street

Lake Street assumed coverage of Avita Medical (RCEL) with a Buy rating and a price target of $8,...

4d ago

RCEL

Avita Medical downgraded to Sell from Neutral at BTIG

BTIG downgraded Avita Medical (RCEL) to Sell from Neutral with a $3 price target The company reported another...

7d ago

RCEL

Avita Medical reports 2Q EPS (38c), consensus (36c)

Reports Q2 revenue $18.42M vs. $15.2M last year. Jim Corbett, Chief Executive Officer of Avita Medical (RCEL), commented:...

8d ago

RCEL

Avita Medical cuts FY25 revenue view to $76M-$81M from $100M-$106M

Consensus $152.1M. The company said, “As a result of slower than expected sales in the first half, significantly...

8d ago

RCEL

Avita Medical chair Lou Panaccio steps down, Cary Vance succeeds

Avita Medical (RCEL) announced that Lou Panaccio has stepped down from the position of board chair, and that...

8d ago

RCEL

Avita Medical’s Earnings Call: Growth Amid Challenges

Avita Medical Ltd (($RCEL)) has held its Q2 earnings call. Read on for the main highlights of the...

3d ago

RCEL

Avita Medical Raises $15M in Private Placement

Avita Medical ( ($RCEL) ) just unveiled an announcement. On August 12, 2025, AVITA Medical announced the successful...

3d ago

RCEL

AVITA Medical Reports Q2 2025 Financial Results

Avita Medical Ltd ( ($RCEL) ) has released its Q2 earnings. Here is a breakdown of the information...

8d ago

RCEL

Avita Medical Amends Credit Agreement with OrbiMed

An announcement from Avita Medical ( ($RCEL) ) is now available. On August 7, 2025, AVITA Medical announced...

8d ago

RCEL

Avita Medical Appoints Dr. Michael Tarnoff to Board

The latest announcement is out from Avita Medical ( ($RCEL) ). On August 6, 2025, AVITA Medical announced...

9d ago

RCEL

RCEL Earnings this Week: How Will it Perform?

Avita Medical Ltd (RCEL) is scheduled to report 2nd quarter earnings on 08/07/2025, after the market closes. Regarding...

11d ago

RCEL

Avita Medical’s Cohealyx Study: A Promising Step in Wound Care Innovation

Avita Medical Ltd (($RCEL)) announced an update on their ongoing clinical study. Avita Medical Ltd is conducting a...

14d ago

RCEL

Avita Medical’s Cohealyx Study: A Game Changer in Wound Management?

Avita Medical Ltd (($RCEL)) announced an update on their ongoing clinical study. Avita Medical Ltd is conducting a...

16d ago

RCEL

RCEL FAQ

What was Avita Medical’s price range in the past 12 months?

Avita Medical lowest stock price was $3.60 and its highest was $14.16 in the past 12 months.

What is Avita Medical’s market cap?

Avita Medical’s market cap is $154.39M.

When is Avita Medical’s upcoming earnings report date?

Avita Medical’s upcoming earnings report date is Nov 06, 2025 which is in 83 days.

How were Avita Medical’s earnings last quarter?

Avita Medical released its earnings results on Aug 07, 2025. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.13.

Is Avita Medical overvalued?

According to Wall Street analysts Avita Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Avita Medical pay dividends?

Avita Medical does not currently pay dividends.

What is Avita Medical’s EPS estimate?

Avita Medical’s EPS estimate is -0.29.

How many shares outstanding does Avita Medical have?

Avita Medical has 26,618,935 shares outstanding.

What happened to Avita Medical’s price movement after its last earnings report?

Avita Medical reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went down -21.004%.

Which hedge fund is a major shareholder of Avita Medical?

Among the largest hedge funds holding Avita Medical’s share is Hussman Strategic Advisors Inc. It holds Avita Medical’s shares valued at 0.

Avita Medical Stock Smart Score

Neutral

Fundamentals

Return on Equity

-935.73%

Trailing 12-Months

Asset Growth

-33.81%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Avita Medical

AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.

Avita Medical (RCEL) Earnings & Revenues

Historic Earnings Reports

RCEL Company Deck

RCEL Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant growth in commercial revenue and promising clinical data for RECELL and Cohealyx, along with strategic partnerships and operational efficiencies. However, these positives were tempered by challenges related to reimbursement delays, a lowered financial forecast, reduced cash reserves, and delayed international expansion.View all RCEL earnings summaries

RCEL Revenue Breakdown

99.27% Commercial sales

0.67% Services for emergency preparedness

0.07% Deferred commercial revenue

RCEL Stock 12 Month Forecast

Average Price Target

$8.70

▲(50.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","11":"$11","20":"$20","6.5":"$6.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$19.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,6.5,11,15.5,20],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,6.224615384615385,7.28923076923077,8.353846153846153,9.418461538461539,10.483076923076922,11.547692307692307,12.612307692307692,13.676923076923076,14.741538461538461,15.806153846153846,16.87076923076923,17.935384615384613,{"y":19,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,5.432307692307693,5.704615384615384,5.976923076923077,6.249230769230769,6.521538461538461,6.793846153846154,7.066153846153846,7.338461538461538,7.610769230769231,7.883076923076922,8.155384615384616,8.427692307692308,{"y":8.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.16,4.993846153846154,4.827692307692308,4.661538461538462,4.495384615384616,4.32923076923077,4.163076923076924,3.996923076923077,3.830769230769231,3.664615384615385,3.4984615384615387,3.332307692307692,3.166153846153846,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.06,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.55,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.65,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.72,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.04,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >